LncRNA EGFR-AS1 Modulates Ferroptosis to Decrease Cervical Cancer Radiosensitivity via the m6A/IGF2BP3/APAF1 Pathway
By
Xianglong Chen
Jingyu Li
Yujie Sun
Zhaoyu Ye
Man Long
Junguo Bu
Zirong Fan
Zhaojing Jiang
March 5, 2026
Clinical Scorecard: LncRNA EGFR-AS1 Modulates Ferroptosis to Decrease Cervical Cancer Radiosensitivity via the m6A/IGF2BP3/APAF1 Pathway
At a Glance
Category Detail
Condition Key Mechanisms Target Population Patients with cervical cancer, particularly those with advanced stages. Care Setting
Key Highlights
m6A modification is implicated in the regulation of cervical cancer cell behavior. Guideline-Based Recommendations
Diagnosis
Assess cervical cancer stage and radiotherapy sensitivity through histological analysis. Incorporate lncRNA analysis in diagnosis. Management
Utilize radical radiotherapy for intermediate and advanced cervical cancer stages. Consider lncRNA analysis in treatment planning. Monitoring & Follow-up
Risks
Patient & Prescribing Data
Investigate lncRNA and ferroptosis pathways to improve treatment outcomes, focusing on specific lncRNAs.
Clinical Best Practices
Incorporate lncRNA analysis in treatment planning for cervical cancer using specific assays. Explore ferroptosis in therapeutic strategies to enhance radiotherapy efficacy. Related Resources & Content
